PCVX vs PHGE

Vaxcyte, Inc. vs BiomX Inc. — Valuation Comparison 2026

PCVX

Biological Products, (No Diagnostic Substances)
Vaxcyte, Inc.
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$51.40
Last close
Models
10/13
Active
VS

PHGE

Biological Products, (No Diagnostic Substances)
BiomX Inc.
Quality
3.3
out of 10
Value Trap
44
WARN
Price
$1.26
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PCVX Fair ValuePCVX Upside PHGE Fair ValuePHGE Upside
Bayesian DCF Intrinsic $14.79 -71.2% $0.48 -56.9%
Earnings Power Value Intrinsic $27.17 -54.3%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $15.19 -70.5% $2.33 +85.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PCVX vs PHGE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PCVX vs PHGE — Which Stock Is More Undervalued?

PCVX scores higher with a 5.1/10 quality rating vs PHGE's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vaxcyte, Inc. (PCVX) and BiomX Inc. (PHGE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PCVX currently trades at $51.40 with a QOC of 5.1/10, while PHGE trades at $1.26 with a QOC of 3.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).